Computational Identification of Antigen-Binding Antibody Fragments
暂无分享,去创建一个
[1] R. Porter. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. , 1959, The Biochemical journal.
[2] F. Karush,et al. THE SUBUNITS OF PURIFIED RABBIT ANTIBODY. , 1964, Biochemistry.
[3] D. Pressman,et al. Specific Binding Activity of Isolated Light Chains of Antibodies , 1967, Science.
[4] C. Selve,et al. Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.) , 1975 .
[5] Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression. , 1985, Journal of immunology.
[6] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[7] J. Blalock,et al. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. , 1988, Science.
[8] J. Wells,et al. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.
[9] P. T. Jones,et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.
[10] Development of biologically active peptides based on antibody structure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[11] G. Fields,et al. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.
[12] E. Giralt,et al. Cyclization of disulfide-containing peptides in solid-phase synthesis. , 2009, International journal of peptide and protein research.
[13] B. Persson,et al. Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins , 1991 .
[14] E. Kabat,et al. Sequences of proteins of immunological interest , 1991 .
[15] M Kahn,et al. Design and synthesis of a mimetic from an antibody complementarity-determining region. , 1991, Science.
[16] D. Weiner,et al. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. , 1991, The Journal of biological chemistry.
[17] M. Berry,et al. Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. , 1992, Journal of chromatography.
[18] V. Garsky,et al. Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. , 1992, The Journal of biological chemistry.
[19] B. Wahrén,et al. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[20] E. Lasonder,et al. Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. , 1994, Journal of chromatography. A.
[21] K. Tsumoto,et al. Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. , 1994, Biochemical and biophysical research communications.
[23] V. Ose,et al. Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. , 1996, Human antibodies and hybridomas.
[24] D. Myszka,et al. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. , 1997, Current opinion in biotechnology.
[25] D. Laune,et al. Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins* , 1997, The Journal of Biological Chemistry.
[26] J. Scardina,et al. Peptides Derived from the Complementarity-determining Regions of Anti-Mac-1 Antibodies Block Intercellular Adhesion Molecule-1 Interaction with Mac-1* , 1998, The Journal of Biological Chemistry.
[27] S. Shapiro,et al. Cardiolipin binding a light chain from lupus-prone mice. , 1998, Biochemistry.
[28] D. Phillips,et al. Structure‐based design of peptides that recognize the CD4 binding domain of HIV‐1 gp120 , 1998, AIDS.
[29] A. Bogan,et al. Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.
[30] P. Pothier,et al. Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice , 1998, Journal of Virology.
[31] G. Johnson,et al. Preferred CDRH3 lengths for antibodies with defined specificities. , 1998, International immunology.
[32] K. Tsumoto,et al. Crystal Structure of Anti-Hen Egg White Lysozyme Antibody (HyHEL-10) Fv-Antigen Complex , 1999, The Journal of Biological Chemistry.
[33] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[34] Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. , 2000, Biochemistry. Biokhimiia.
[35] Donald M. O'Rourke,et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo , 2000, Nature Biotechnology.
[36] A. Berezov,et al. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. , 2001, Journal of medicinal chemistry.
[37] K. Tsumoto,et al. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity‐determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target , 2002, FEBS letters.
[38] L. Serrano,et al. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.
[39] P. Hudson,et al. Engineered antibodies , 2003, Nature Medicine.
[40] A. M. Stanley,et al. Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .
[41] J. C. Almagro,et al. Identification of differences in the specificity‐determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires , 2004, Journal of molecular recognition : JMR.
[42] F. Dammacco,et al. Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. , 2004, Immunology letters.
[43] Yan Li,et al. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. , 2005, Immunology letters.
[44] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[45] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[46] B. Cai,et al. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting , 2007, Nature Biotechnology.
[47] S. Batra,et al. Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.
[48] K. Tsumoto,et al. Structural Consequences of Mutations in Interfacial Tyr Residues of a Protein Antigen-Antibody Complex , 2007, Journal of Biological Chemistry.
[49] Haruki Nakamura,et al. Structural classification of CDR‐H3 revisited: A lesson in antibody modeling , 2008, Proteins.
[50] M. Juliano,et al. Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities , 2008, PloS one.
[51] T. Knöchel,et al. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. , 2008, Cancer cell.
[52] Ruth Nussinov,et al. Computational Protein-Protein Interactions , 2009 .
[53] J. Desmet,et al. A Combinatorial Approach for the Design of Complementarity-determining Region-derived Peptidomimetics with in Vitro Anti-tumoral Activity* , 2009, The Journal of Biological Chemistry.
[54] Janice M Reichert,et al. Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.
[55] Yanay Ofran. Prediction of Protein Interaction Sites , 2009 .
[56] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[57] S. Dübel,et al. Antibody Engineering , 2010, Springer Berlin Heidelberg.
[58] Christian Bailly,et al. Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.
[59] Holger Gohlke,et al. DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein–protein interactions , 2010, Nucleic Acids Res..
[60] D. Ponde,et al. Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. , 2011, Bioorganic & medicinal chemistry letters.
[61] Lora Hamuro,et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] , 2011, Journal of Lipid Research.
[62] Jinyan Li,et al. Antibody-Specified B-Cell Epitope Prediction in Line with the Principle of Context-Awareness , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[63] E. Baba,et al. [Development trends for therapeutic antibody]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.